Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (127)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (285)
  2. Breast Medicine Service (285)
  3. Department of Medicine (285)
  4. GSK Faculty (285)
  5. Human Oncology and Pathogenesis Program (285)
  6. Solid Tumor Oncology Division (285)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (57)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (15)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response
    Meeting Abstract

    Mai, N.; Safonov, A.; Marra, A.; Chen, Y.; Chandarlapaty, S.; Razavi, P.; Plitas, G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Quality of life in patients with malignant wounds treated at a wound care clinic
    Meeting Abstract

    Chen, A.; Dusza, S. W.; Bromberg, J.; Chandarlapaty, S.; Goldfarb, S. B.; Sanford, R. A.; Markova, A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
    Meeting Abstract

    Green, A.; Zhou, Q.; Iasonos, A.; Zammarrelli, W.; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Hom, V.; Erinjeri, J. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer
    Journal Article

    Mai, N.; Chen, J. F.; Rana, S.; Robson, M.; Chandarlapaty, S.; Rosen, E. Y.
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
    Journal Article

    Liu, S. Y.; Erazo, T.; Jee, J.; Arfe, A.; Gupta, A.; Pike, L. R. G.; Santini, F. C.; Daly, B.; Schoenfeld, A.; Eichholz, J.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • RB1 genetic alterations in estrogen receptor–positive breast carcinomas: Correlation with neuroendocrine differentiation
    Journal Article

    Schwartz, C. J.; Marra, A.; Selenica, P.; Gazzo, A.; Tan, K.; Ross, D.; Razavi, P.; Chandarlapaty, S.; Weigelt, B.; Reis-Filho, J. S.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)
    Meeting Abstract

    Loi, S.; Johnston, S. R. D.; Arteaga, C. L.; Graff, S. L.; Chandarlapaty, S.; Goetz, M. P.; Desmedt, C.; Sasano, H.; Liu, D.; Rodrik-Outmezguine, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—A position statement from the ETOP IBCSG Partners Foundation
    Review

    Peters, S.; Loi, S.; André, F.; Chandarlapaty, S.; Felip, E.; Finn, S. P.; Jänne, P. A.; Kerr, K. M.; Munzone, E.; Passaro, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save